Binnopharm Group, a holding company that combines Sistema’s pharmaceutical assets, has announced plans to unite all its research divisions into a cutting-edge R&D hub in the Krasnogorsk District, Moscow Region. The project envisages the construction of two centres charged with developing chemically synthesised and biotechnological medicines, respectively. The investment will amount to RUB 2.5 bn.
A pharmaceutical development centre with a pilot site to make solid and soft dosage forms will come on stream as early as in Q1 2022. The next stage will see the launch of R&D and pilot production of biotechnological medicines. A 12,000 sq m centre will employ around 450 experts.
Rustem Muratov, CEO of Binnopharm Group, said:
The unique project will bring together chemical and biotechnological laboratories focused on medicine development. By consolidating our intellectual capital and fitting our R&D centres with the state-of-the-art equipment, we can take the pharmaceutical development to a whole new level and create medicines of any complexity, including biotechnological ones. Our R&D hub will enable us to annually upgrade more than 10% of our product portfolio. By 2025, we will be well positioned to market over 100 medical products for dermatology, neurology, gynaecology, paediatrics, and other disease areas. What’s more, we plan to create an EU- and FDA-certified production site and quality control laboratory to tap into foreign markets.